Related Experiment Video
Updated: Jan 5, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Lin28a protects against diabetic cardiomyopathy through Mst1 inhibition
Penghua You1,2, Zheng Cheng1, Xiaomin He3
1Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
Abstract:
Lin28a has been found to enhance glucose uptake and insulin sensitivity. Lin28a alleviates cardiac dysfunction under various pathological conditions. However, the effects and underlying mechanisms of Lin28a on diabetic cardiomyopathy (DCM) are not well-understood. The aim of this study was to determine whether Lin28a protects against DCM and the potential mechanisms. Two to three days old mouse neonatal primary cardiomyocytes were randomized for treatment with adenoviruses harboring Lin28a and mammalian sterile 20-like kinase 1 (Mst1) short hairpin RNA, 48 hr before culturing in normal or high glucose medium. Cardiomyocyte apoptosis, autophagy, mitochondrial morphology, adenosine triphosphate content, and cytokine levels in the high glucose or normal conditions were observed between all groups. Either Lin28a overexpression or Mst1 knockdown alleviated mitochondrial ultrastructure impairment, decreased cytokine levels, inhibited apoptosis, and enhanced autophagy in primary neonatal mouse cardiomyocytes treated with high glucose. Importantly, the protective effects of Lin28a and Mst1 disappeared after treatment with 3-methyladenine, an autophagy inhibitor. Interestingly, in Mst1 knockdown cardiomyocytes, Lin28a overexpression failed to further enhance autophagy and alleviate high glucose-induced cardiomyocyte injury, which implies the protective roles of Lin28a counteracting high glucose-induced cardiomyocyte injury are dependent on Mst1 inhibition. Furthermore, co-immunoprecipitation and immunofluorescence double staining suggested that there were no direct interactions between Mst1 and Lin28a. Lin28a increased the expression of Akt, which inhibited the activation of Mst1-mediated apoptotic pathways.
Insights
Lin28a protects against diabetic cardiomyopathy by inhibiting Mst1 and promoting autophagy. This study reveals Lin28a
Area of Science:
- Cardiovascular Biology
- Metabolic Diseases
- Cellular Mechanisms
Background:
- Diabetic cardiomyopathy (DCM) involves cardiac dysfunction due to diabetes.
- Lin28a is known to improve glucose metabolism and insulin sensitivity.
- The specific role of Lin28a in DCM pathogenesis remains unclear.
Purpose of the Study:
- To investigate the protective effects of Lin28a against DCM.
- To elucidate the underlying molecular mechanisms of Lin28a in DCM.
Main Methods:
- Primary neonatal mouse cardiomyocytes were treated with Lin28a or Mst1 shRNA under high glucose conditions.
- Assessed cardiomyocyte apoptosis, autophagy, mitochondrial function, and cytokine levels.
- Utilized autophagy inhibitor (3-methyladenine) and Mst1 knockdown to explore pathway dependency.
Main Results:
- Lin28a overexpression and Mst1 knockdown mitigated high glucose-induced cardiomyocyte injury.
- Both interventions improved mitochondrial morphology, reduced apoptosis, and enhanced autophagy.
- Protective effects were dependent on autophagy and Mst1 inhibition, with Lin28a acting via Akt to inhibit Mst1.
Conclusions:
- Lin28a protects cardiomyocytes from high glucose injury by inhibiting Mst1 and promoting autophagy.
- Lin28a's protective effects in DCM are mediated through the Akt/Mst1 pathway.
- Targeting Lin28a may offer a therapeutic strategy for diabetic cardiomyopathy.

